Skip to main content

Table 4 Correlation between different levels of miR-124-3 methylation and clinical parameters

From: Pyrosequencing quantified methylation level of miR-124 predicts shorter survival for patients with myelodysplastic syndrome

Variables No. miR-124-3 methylation P
  Low-meth (n%) High-meth (n%)
Sex     0.150
 Male 36 11(30.6) 25(69.4)
 Female 20 10(50.0) 10(50.0)
Age     0.015
  < 60 25 5(20.0) 20(80.0)
  ≥ 60 31 16(51.6) 15(48.4)
WBC (× 109/L)     1.000
  ≥ 4 13 5(38.5) 8(61.5)
  < 4 43 16(37.2) 27(62.8)
Hb(g/dL)     0.715
  ≥ 10 9 4(44.4) 5(55.6)
  < 10 47 17(36.2) 30(63.8)
PLT (× 109/L)     0.184
  ≥ 100 18 9(50.0) 9(50.0)
  < 100 38 12(31.6) 26(68.4)
MCV(fL)     0.783
  ≥ 100 28 11(39.3) 17(60.7)
  < 100 28 10(35.7) 18(64.3)
WHO classification     0.006
 SLD/RS-SLD/
MDS-U/5q-
10 7(70.0) 3(30.0)
 MLD/RS-MLD 10 6(60.0) 4(40.0)
 EB-1/EB-2 36 8(22.2) 28(77.8)
BM blast (%)     0.006
  < 5 20 13(65.0) 7(35.0)
 5–10 15 3(20.0) 12(80.0)
 11–19 21 5(23.8) 16(76.2)
Cytopenias     0.298
 0/1 11 6(54.5) 5(45.5)
 2/3 45 11(33.3) 30(66.7)
Karyotype     0.888
 Good 34 13(38.2) 2 (61.8)
 Intermediate 7 2(28.6) 5(71.4)
 Poor 14 5(35.7) 9(64.3)
IPSS     0.358
 Low 4 3(75.0) 1(25.0)
 Int-1 24 9(37.5) 15(62.5)
 Int-2 19 6(31.6) 13(68.4)
 High 8 2(25.0) 6(75.0)
  1. Italics are statistically significant